The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

Plain-language summary

Published 2023 in Geroscience, this work by Yi L and collaborators tackles a specific question within safety-focused NMN/NAD+ research.

Key findings reported by the authors

• Human study published in Geroscience (2023) examining The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy ...
• Provides clinical-grade evidence on NAD+/NMN-related outcomes in human participants
• First author: Yi L; cited frequently in NMN supplementation discussions

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to safety decisions, with secondary relevance to dosage. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.